Pertinax Therapeutics Inc.;Microconstants China Inc.
发明人:
Beverly James Incledon,Yiu-Chung Lee,Qicheng David Yang
申请号：
US15119931
公开号：
US20170143787A1
申请日:
2014.02.19
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A method for treating various types of cancer/tumor by administering the combination of SDF-1 antagonist, in particular, that specifically binds to human CXCR4, and another chemotherapeutic agent, or a radiation therapy, during an embolization therapy. Such combination therapies exhibit synergistic effects compared to the treatment with either agent alone. Thus, the method is particularly beneficial for cancer patients who have low tolerance to the side effects caused by high dosages required for the treatment by either agent alone.
